Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10.

Slides:

Advertisements

Similar presentations

Treatment of HBV/HCV Coinfection

Advertisements

Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10.

Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment Response Henry Lik–Yuen Chan, Vincent.

Volume 39, Issue 6, Pages (December 2003)

Volume 50, Issue 4, Pages (April 2009)

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

R. Cavallo Clinical Microbiology and Infection

Cryptococcosis—the impact of delay to diagnosis

Evolution of the incidence of hepatitis B virus infection and immunization rates in a large French cohort born between 1960 and 1994 C. Ramière, L. Roche,

Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract A. Torres-Cornejo, O.J.

Intact interferon-γ response against Coxiella burnetii by peripheral blood mononuclear cells in chronic Q fever T. Schoffelen, J. Textoris, C.P. Bleeker-Rovers,

Effect of highly active anti-retroviral therapy and hepatitis C virus co-infection on serum levels of pro-inflammatory and immunoregulatory cytokines.

Core I97L mutation in conjunction with P79Q is associated with persistent low HBV DNA and HBs antigen clearance in patients with chronic hepatitis B

Intrahepatic hepatitis B virus replication and liver histology in subjects with occult hepatitis B infection D.K.-H. Wong, J. Fung, C.-K. Lee, W.-K.

Comparison of the safety and immunogenicity of live attenuated and inactivated hepatitis A vaccine in healthy Chinese children aged 18 months to 16 years:

Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following.

Immune-driven adaptation of hepatitis B virus genotype D involves preferential alteration in B-cell epitopes and replicative attenuation—an insight from.

Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care S. Chevaliez,

Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis T. Steinmetz, N.

Association of CD209L tandem repeats polymorphism with susceptibility to human immunodeficiency virus-1 infection, disease progression, and treatment.

S. J. Hullegie, J. E. Arends, B. J. A. Rijnders, W. L. Irving, D

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Hepatitis B and C virus-related carcinogenesis

Infectious causes of cancer: an evolving educational saga

Virological tools to diagnose and monitor hepatitis C virus infection

Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen–positive chronic.

Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective.

Hepatitis B virus basal core promoter/precore mutants and association with liver cirrhosis in children with chronic hepatitis B virus infection Y.W.

Comparison of the safety and immunogenicity of live attenuated and inactivated hepatitis A vaccine in healthy Chinese children aged 18 months to 16 years:

Volume 68, Issue 3, Pages (March 2018)

E. Galmozzi, F. Facchetti, R. Perbellini, A. Aghemo

Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B W.-K. Seto, D. K.-H. Wong,

Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency Danny Ka-Ho Wong, Wai-Kay.

F. Li, P. Zhou, W. Deng, J. Wang, R. Mao, Y. Zhang, J. Li, J. Yu, F

Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain J.-M. Aguado, C. Lumbreras, D.

Hepatitis C: global epidemiology and strategies for control

M. De Fost, W. Chierakul, R. Limpaiboon, A. Dondorp, N. J. White, T

L. -W. Song, P. -G. Liu, C. -J. Liu, T. -Y. Zhang, X. -D. Cheng, H. -L

A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen- positive patients: a prospective cohort study in China Y. Zhang,

The added value of hepatitis E diagnostics in determining causes of hepatitis in routine diagnostic settings in the Netherlands M.H.E. Doting, J. Weel,

Ming-Ling Chang, Yun-Fan Liaw Journal of Hepatology

Volume 68, Issue 4, Pages (April 2018)

New HCV therapies on the horizon

Epidemiology of opportunistic infections in AIDS patients

C. Fabrizio, A. Procopio Clinical Microbiology and Infection

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman Clinical.

A. Pierangeli, F. Cannella, C. Scagnolari, M. Gentile, I. Sciandra, G

Y. -P. Ding, M. -F. Liang, J. -b. Ye, Q. -h. Liu, C. -h. Xiong, B

Serum hepatitis B core-related antigen is more accurate than hepatitis B surface antigen to identify inactive carriers, regardless of hepatitis B virus.

Volume 139, Issue 1, Pages e4 (July 2010)

Hepatitis B and C virus-related carcinogenesis

S. David, M. Mentasti, J. Parkhill, V.J. Chalker

Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected.

The role of quantitative hepatitis B surface antigen revisited

Evidence for human immunodeficiency virus and Cryptococcus neoformans interactions in the pro-inflammatory and anti-inflammatory responses in blood during.

Volume 50, Issue 4, Pages (April 2009)

F. M. Moesker, J. J. A. van Kampen, A. A. van der Eijk, A. M. C

Accurate hepatitis C virus genotyping and selection of optimal therapy: lessons from a St Petersburg strain infection E. Knops, E. Heger Clinical Microbiology.

Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy L. Boglione,

H. Leblebicioglu, C. Eroglu Clinical Microbiology and Infection

Increased intrahepatic quasispecies heterogeneity correlates with off-treatment sustained response to nucleos(t)ide analogues in e antigen-positive chronic.

Dynamics of hepatitis B virus quasispecies heterogeneity in association with nucleos(t)ide analogue treatment determined by MALDI-TOF MS M. Rybicka,

Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients H.-Y. Pan, H.-Y. Pan,

Amplification and pyrosequencing of near-full-length hepatitis C virus for typing and monitoring antiviral resistant strains P. Trémeaux, A. Caporossi,

Volume 55, Issue 5, Pages (November 2011)

Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment Response Henry Lik–Yuen Chan, Vincent.

Shorter duration of antibiotic treatment for acute bacteraemic cholangitis with successful biliary drainage: a retrospective cohort study A. Doi, T.

Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction? Masaru Enomoto, Yoshiki Murakami,

The burden of chikungunya in the Pacific

Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients D. He, S. Guo, P. Zhu, S. Tao, M. Li,

Presentation transcript:

Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV- coinfected patients S.B. Wiegand, J. Jaroszewicz, A. Potthoff, C. Höner zu Siederdissen, B. Maasoumy, K. Deterding, M.P. Manns, H. Wedemeyer, M. Cornberg Clinical Microbiology and Infection Volume 21, Issue 7, Pages 710.e1-710.e9 (July 2015) DOI: 10.1016/j.cmi.2015.03.003 Copyright © 2015 Terms and Conditions

Fig. 1 Correlation of hepatitis B surface antigen (HBsAg) and (a) hepatitis B virus (HBV) DNA; (b) hepatitis C virus (HCV) RNA; (c) serum HBsAg levels in HBV/HCV coinfection according to viral dominance (column a, HBV-dominant; b, HCV-dominant; c, both dominant; d, none dominant) and (d) HBsAg levels in HCV dominant group versus HBV-monoinfected patients (column b, HCV-dominant HBV/HCV coinfection; e, HBV-monoinfected patients after achieving viral response on nucleos(t)ide analogue (NA) therapy; f, HBV-monoinfected low replicative patients). Clinical Microbiology and Infection 2015 21, 710.e1-710.e9DOI: (10.1016/j.cmi.2015.03.003) Copyright © 2015 Terms and Conditions

Fig. 2 The association between long-term hepatitis C virus (HCV) RNA and hepatitis B surface antigen (HBsAg) dynamics in hepatitis B virus (HBV)/HCV-coinfected patients (a) with HCV RNA increase in follow up and (b) with stable HCV RNA. Horizontal bars denote median value at baseline (blue) and last follow up (red). (c) Correlation between 'HCV RNA and 'HBsAg from baseline to last follow up in HBV/HCV-coinfected patients. Clinical Microbiology and Infection 2015 21, 710.e1-710.e9DOI: (10.1016/j.cmi.2015.03.003) Copyright © 2015 Terms and Conditions

Fig. 3 (a) Correlation between baseline hepatitis C virus (HCV) RNA and serum interferon γ-induced protein 10 (IP-10) in hepatitis B virus (HBV)/HCV coinfection. (b) Serum IP-10 concentration in HBV/HCV coinfection versus HBV-monoinfected patients (i, HBV-dominant HBV/HCV coinfection: ii, HCV-dominant HBV/HCV co-infection; iii, HBV/HCV dominant; iv, HBV monoinfection before nucleos(t)ide analogue (NA) therapy; v, HBV monoinfection on NA at viral response; vi, HBV monoinfection with hepatitis B surface antigen decline >1.0 log10 on NA at baseline). Clinical Microbiology and Infection 2015 21, 710.e1-710.e9DOI: (10.1016/j.cmi.2015.03.003) Copyright © 2015 Terms and Conditions

Fig. S1 Correlation of hepatitis B surface antigen (HBsAg) levels measured with Abbott Architect and Roche Elecsys in hepatitis B virus/hepatitis C virus-coinfected patients. Clinical Microbiology and Infection 2015 21, 710.e1-710.e9DOI: (10.1016/j.cmi.2015.03.003) Copyright © 2015 Terms and Conditions